The omega-3 market is estimated at USD 4,362.2 million in 2025 and is projected to reach USD 7,756.4 million by 2030, registering a CAGR of 12.2% during the forecast period. The market’s robust growth is primarily driven by rising consumer awareness of omega-3’s health benefits—particularly its role in supporting cardiovascular, cognitive, visual, and joint health.
Since the human body cannot efficiently synthesize key omega-3 fatty acids like EPA and DHA, consumers are increasingly turning to dietary supplements, fortified foods, and pharmaceutical formulations to meet their nutritional needs. Omega-3 oils’ versatility allows their incorporation into various formats—such as capsules, powders, beverages, and functional foods—without compromising stability or bioavailability.
Fish oil, krill oil, and algal-based omega-3 remain the most preferred sources, backed by strong scientific validation of their safety and efficacy. Additionally, growing consumer demand for clean-label, sustainable, and plant-based products is expected to further propel market expansion in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227
By Type: DHA Segment to Register the Fastest Growth
Docosahexaenoic acid (DHA), a polyunsaturated omega-3 fatty acid, is projected to be the fastest-growing type segment during the forecast period. DHA plays a vital structural role in both the brain and eyes, comprising up to 97% of omega-3 fats in the brain and 93% in the retina.
Key DHA sources include fish, fish oils, dairy products, and specialty eggs, with marine species such as salmon and tuna offering particularly high concentrations (around 1.2 g of DHA per serving).
DHA is also a crucial component of cardiac tissue and is essential for infant brain development and normal adult cognitive function. Epidemiological studies associate adequate DHA intake with a reduced risk of Alzheimer’s disease and improved neuronal communication due to enhanced membrane fluidity.
Given its central role in neurological and visual development, DHA finds extensive use in infant nutrition, dietary supplements, and functional foods. Strong demand from both developed and emerging markets ensures DHA’s continued dominance over other omega-3 types such as EPA and ALA.
By Application: Infant Formulas to Record the Highest CAGR
The infant formulas segment is expected to witness the highest CAGR in the omega-3 market. The rising recognition of DHA’s critical role in infant brain and eye development—endorsed by organizations such as the World Health Organization (WHO) and the European Food Safety Authority (EFSA)—is driving widespread adoption.
The growing population of working mothers and increasing dependence on formula feeding have fueled global demand for DHA- and EPA-fortified infant formulas. Manufacturers are introducing premium formulations that closely replicate the fatty acid profile of human breast milk.
Regulatory mandates, such as the EU’s requirement since 2020 for DHA inclusion in all infant and follow-on formulas (minimum 20 mg/100 kcal and maximum 50 mg/100 kcal), have further accelerated market growth.
Additionally, growing preference for organic and clean-label infant nutrition products, coupled with rising birth rates and disposable incomes in emerging economies, is expected to sustain this upward trend through 2030.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=227
Regional Insights: Europe to Hold a Significant Market Share
Europe is anticipated to maintain a prominent position in the global omega-3 market, supported by strong regulatory frameworks, high consumer awareness, and an increasing shift toward preventive healthcare.
European consumers show strong demand for premium dietary supplements and sustainable omega-3 sources, particularly plant- and algal-based alternatives. Countries such as Germany, the UK, and France are seeing a rise in vegetarian and flexitarian consumers, which has bolstered demand for algal-derived omega-3s.
The European Food Safety Authority (EFSA) continues to highlight the cognitive and ocular benefits of omega-3s, contributing to their widespread adoption. Major players such as Pelagia AS (Norway), Corbion (Netherlands), and dsm-firmenich (Netherlands) are at the forefront of innovation and capacity expansion.
Recent developments include Corbion’s launch of AlgaVia and Pelagia’s investment in new omega-3 concentrate production facilities. Meanwhile, BASF SE (Germany) has introduced microencapsulated omega-3 powders with extended shelf life to cater to evolving European demand.
The European Society of Cardiology (ESC) has also reinforced omega-3’s benefits in reducing cardiovascular disease risks, further boosting regional consumption. As a result, European manufacturers continue to invest in dietary supplements, functional foods & beverages, and pharmaceutical-grade omega-3 applications.
Key Market Players
Prominent companies operating in the omega-3 market include:
BASF SE (Germany), Cargill, Incorporated (US), dsm-firmenich (Netherlands), ADM (US), Kerry Group plc (Ireland), Aker BioMarine (Norway), Croda International plc (UK), Corbion (Netherlands), Pelagia AS (Norway), KD Pharma Group SA (Switzerland), GC Rieber (Norway), Cooke Aquaculture Inc. (Canada), Golden Omega (Chile), Polaris (France), BTSA (Spain), KinOmega Biopharm Inc. (China), Rimfrost AS (Norway), Mara Renewables (Canada), Cellana Inc. (US), and AlgaeCytes Limited (UK).
